The Life Cycle of Cutaneous T Cell Lymphoma Reveals Opportunities for Targeted Drug Therapy

E-ISSN： 1873-5576|4|7|609-619

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.4, Iss.7, 2004-11, pp. : 609-619

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Emerging drugs in cutaneous T cell lymphoma

By Mestel Dominik Sebastian Assaf Chalid Steinhoff Matthias Beyer Marc Moebs Markus Sterry Wolfram

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 2, 2008-06 ,pp. : 345-361

Informa Healthcare

Access to resources Recommend Favorite

Etretinate as an Effective Adjunctive Therapy for Recalcitrant Palmar/Plantar Hyperkeratosis in Patients with Erythrodermic Cutaneous T Cell Lymphoma Undergoing Photopheresis

By LIM HENRY W. HARRIS H. ROSS

Dermatologic Surgery, Vol. 21, Iss. 7, 1995-07 ,pp. : 597-599

Elsevier

Access to resources Recommend Favorite

Anti-CD3 Recombinant Diphtheria Immunotoxin Therapy of Cutaneous T Cell Lymphoma

Current Drug Targets, Vol. 10, Iss. 2, 2009-02 ,pp. : 104-109

Bentham Science Publishers

Access to resources Recommend Favorite

Alemtuzumab: Cutaneous T cell lymphoma transformation in an elderly patient: case report

Reactions Weekly, Vol. 1, Iss. 1170, 2007-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite